StoxLaurus Labs vs Cipla: share price & financials comparison
NSE: LAURUSLABS vs CIPLA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Laurus Labs vs Cipla at a glance
Laurus Labs (LAURUSLABS) has a market capitalisation of ₹1,26,430 Cr, against ₹1,13,988 Cr for Cipla (CIPLA). Over the past year Laurus Labs has returned +143.3%, compared with -10.8% for Cipla. On valuation, Cipla trades at a lower P/E of 39.3 versus 94.4. Laurus Labs earns a higher return on equity (22.1% vs 8.2%). Laurus Labs comes out ahead on profitability, growth, momentum and technicals. Cipla comes out ahead on size, valuation and financial health. Across the scored metrics below, Laurus Labs leads on 11 and Cipla on 6. On StoxGud's 10-point checklist, Laurus Labs scores 8/10 and Cipla scores 6/10.
| Metric | Laurus Labs | Cipla |
|---|---|---|
| Size | ||
| Market cap | ₹1,26,430 Cr | ₹1,13,988 Cr |
| Revenue (latest FY) | ₹6,813 Cr | ₹28,163 Cr |
| Net profit (latest FY) | ₹889 Cr | ₹3,879 Cr |
| Valuation | ||
| P/E | 94.4 | 39.3 |
| P/B | 20.86 | 3.22 |
| Dividend yield | 0.07% | 1.13% |
| Profitability | ||
| Return on equity | 22.1% | 8.2% |
| Net profit margin | 17.1% | 10.3% |
| Operating margin | 30.4% | 17.0% |
| Growth | ||
| Revenue growth (YoY) | +33.4% | -2.4% |
| Net profit growth (YoY) | +126.4% | -35.1% |
| Revenue CAGR (multi-year) | +7.2% | +8.0% |
| Financial health | ||
| Debt to equity | 0.41 | 0.01 |
| Momentum | ||
| 1-month return | +14.0% | +6.3% |
| 1-year return | +143.3% | -10.8% |
| 3-year CAGR | +84.5% | +5.4% |
| 5-year CAGR | +36.4% | +9.1% |
| 10-year CAGR | — | +10.0% |
| Distance from 52W high | -2.7% | -8.4% |
| Technicals | ||
| RSI (14) | 71 | 82 |
| Price vs 200-day avg | +58.0% | +3.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Laurus Labs | Cipla |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Laurus Labs or Cipla?
Laurus Labs has a market cap of ₹1,26,430 Cr and Cipla has a market cap of ₹1,13,988 Cr as of 06 Nov 2026.
Which has a lower P/E, Laurus Labs or Cipla?
Cipla has the lower P/E: Laurus Labs trades at 94.4 and Cipla at 39.3.
Which gave better returns in the last year, Laurus Labs or Cipla?
Laurus Labs did better: Laurus Labs returned +143.3% and Cipla returned -10.8% over one year.
Is Laurus Labs or Cipla a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Laurus Labs scores 8/10 and Cipla scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.